$1.01
-0.01(-1.46%)
Mkt Cap $58M
$0.90
$2.52
52-Week Range
At a Glance
AI-generatedTScan Therapeutics reported a net loss of $129.8 million for fiscal year 2025, a slight increase from a $127.5 million loss in 2024.
Revenue breakdown: Reportable Segment (100%).
8-K
TScan Therapeutics, Inc. reported financial results for Q4 and full year 2025, with revenue of $2.6 million in Q4 and $10.3 million for the year, R&D expenses of $20.0 million in Q4 and $114.2 million for the year, and net loss of $23.0 million in Q4 and $129.8 million for the year. Cash and cash equivalents stood at $152.4 million as of December 31, 2025, sufficient to fund operations into the second half of 2027.$58M
Market Cap
$5M
Revenue
-$57M
Net Income
Employees200
Fundamentals
How The Business Makes Money
Revenue by Segment
Reportable Segment100%($13M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001783328
ISINUS89854M1018
CUSIP89854M101
Phone857 399 9500
Address830 Winter Street, Waltham, MA, 02451, US
SEC EDGAR